Research programme: anticancer monoclonal antibodies - AbbVie/Caprion Proteomics
Alternative Names: Lung cancer therapeutics research programme - AbbVie/CaprionLatest Information Update: 04 Nov 2017
At a glance
- Originator Caprion Pharmaceuticals
- Developer AbbVie; Caprion Proteomics
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Non-small cell lung cancer